Today's Information

Provided by: Tanvex BioPharma, Inc.
SEQ_NO 1 Date of announcement 2022/07/25 Time of announcement 11:28:10
Subject 
 Represent subsidiary Tanvex BioPharma USA,Inc.
to announce that TX01(Neupogen Biosimilar) got
Drug Establishment Licence from Health Canada
Date of events 2022/07/20 To which item it meets paragraph 51
Statement 
1.Date of occurrence of the event:2022/07/20
2.Company name:Tanvex BioPharma USA
3.Relationship to the Company (please enter "head office" or
  "subsidiaries"):Subsidiary
4.Reciprocal shareholding ratios:Wholly owned subsidiary of
 Tanvex BioPharma, Inc.
5.Cause of occurrence:TX01(Neupogen Biosimilar) got Drug Establishment
Licence from Health Canada on July 19, 2022(Canada time)
6.Countermeasures:N/A
7.Any other matters that need to be specified:
(1)Name of the product：TX01(Neupogen Biosimilar)
(2)Indication：Neutropenia, caused by chemotherapy for cancer
(3)The next step in development:N/A
(4)Current stage of the Research and Development：
   A.Submit application／Approved／Not approved：
     Got Drug Establishment Licence from Health Canada.
   B.Risks faced by the company, if it failed to receive the approval
     from Governmental Authority：N/A
   C.Future direction if it receives the approval from Governmental
     Authority ：N/A
   D.Cumulative research and development expenses：Due to the
     possibility of future international collaboration of TX01 or
     confidentiality, in order to protect the rights and interests
     of the company and investors, it will not be disclosed.
(5)The next step in development:
   A.Estimated timeline: N/A
   B.Estimated obligations: N/A
(6)Market:According to 2021 IQVIA marketing data, Canada sales of TX01
  (reference Neupogen)(Filgrastim) were approximately CAD$100 million .
(7)Tanvex is a BioTech company that aims to develop biosimilar
   and new drug products. Due to the lengthy R&D process, extensive
   spending, failure to obtain the regulatory approval of government
   authorities which may result in non-productive R&D activities,
   investors should assess carefully the risks of investment.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Tanvex Biopharma Inc. published this content on 25 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 July 2022 03:43:05 UTC.